Nicholas Johnson is a Clinical Trials Statistician at Imperial Clinical Trials Unit (ICTU), School of Public Health.
He has worked in trails across a number of therapeutic areas and is currently investigating cardiovascular interventions (AVATAR and HOPE-HF) as well as EndoBarrier, a sleeve bypass device used to treat Type 2 Diabetes. He has had experience working in Phase I trials and pharmacokinetic (PK) analysis.
Nicholas completed his BSc in Statistics and Computing from the Open University in 2011 and subsequently obtained an MSc (Merit) in Statistics from the University of Kent in 2013.
A keen runner and cat-lover, Nicholas has been with ICTU since October 2015.
et al., 2019, Combined GLP-1, oxyntomodulin, and peptide YY improves body weight and glycemia in obesity and prediabetes/type 2 diabetes: a randomized single-blinded placebo controlled study, Diabetes Care, Vol:42, ISSN:0149-5992, Pages:1446-1453
et al., 2017, A randomised controlled trial of a duodenal-jejunal bypass sleeve device (EndoBarrier) compared with standard medical therapy for the management of obese subjects with type 2 diabetes mellitus, Bmj Open, Vol:7, ISSN:2044-6055